Fulltext present in this item

Thumbnail
Fulltext: 79592.pdf
Format: PDF
Description: publisher's version
Embargo: until further notice
Title: Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
Author(s): L'homme, R.F.A. ; Nijland, H.M.J. ; Gras, L.; Aarnoutse, R.E. ; Crevel, R. van ; Boeree, M.J. ; Brinkman, K.; Prins, J.M.; Juttmann, J.R.; Burger, D.M.
Publication year: 2009
Source: Aids, vol. 23, iss. 7, (2009), pp. 863-865
ISSN: 0269-9370
DOI: https://doi.org/10.1097/QAD.0b013e328329148e
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/79592   https://hdl.handle.net/2066/79592

Display more details
Subject: N4i 3: Poverty-related infectious diseases
NCEBP 13: Infectious diseases and international health
Organization: Internal Medicine
Clinical Pharmacy
Pulmonary Diseases
Journal title:
Aids
Volume: vol. 23
Issue: iss. 7
Page start: p. 863
Page end: p. 865
Abstract:
Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity.

This item appears in the following Collection(s)

Browse

Statistics